StockNews.com Lowers Gilead Sciences (NASDAQ:GILD) to Buy

Gilead Sciences (NASDAQ:GILD) was downgraded by StockNews.com from a “strong-buy” rating to a “buy” rating in a research note issued to investors on Friday.

Other equities analysts also recently issued research reports about the stock. Oppenheimer reissued an “outperform” rating and set a $105.00 price target on shares of Gilead Sciences in a report on Friday. Barclays reduced their price target on shares of Gilead Sciences from $85.00 to $80.00 and set an “equal weight” rating for the company in a report on Monday, February 12th. UBS Group reduced their price target on shares of Gilead Sciences from $81.00 to $75.00 and set a “neutral” rating for the company in a report on Wednesday. Truist Financial downgraded shares of Gilead Sciences from a “buy” rating to a “hold” rating and reduced their price target for the company from $91.00 to $82.00 in a report on Thursday, February 22nd. Finally, Mizuho reduced their price target on shares of Gilead Sciences from $101.00 to $90.00 and set a “buy” rating for the company in a report on Thursday, February 22nd. One research analyst has rated the stock with a sell rating, nine have given a hold rating and six have given a buy rating to the company. According to MarketBeat.com, the company currently has an average rating of “Hold” and an average price target of $84.71.

Gilead Sciences Stock Performance

Gilead Sciences stock opened at $66.76 on Friday. The company has a market cap of $83.12 billion, a PE ratio of 14.84, a P/E/G ratio of 0.91 and a beta of 0.19. The company has a fifty day moving average price of $71.96 and a two-hundred day moving average price of $76.56. The company has a debt-to-equity ratio of 1.08, a current ratio of 1.43 and a quick ratio of 1.27. Gilead Sciences has a 12 month low of $65.90 and a 12 month high of $87.86.

Gilead Sciences (NASDAQ:GILD) last released its quarterly earnings data on Tuesday, February 6th. The biopharmaceutical company reported $1.72 EPS for the quarter, missing analysts’ consensus estimates of $1.76 by ($0.04). The business had revenue of $7.12 billion during the quarter, compared to analyst estimates of $7.10 billion. Gilead Sciences had a return on equity of 38.85% and a net margin of 20.89%. The business’s revenue for the quarter was down 3.7% compared to the same quarter last year. During the same period in the prior year, the firm earned $1.67 EPS. Research analysts expect that Gilead Sciences will post 6.55 earnings per share for the current year.

Insiders Place Their Bets

In other Gilead Sciences news, insider Merdad Parsey sold 2,000 shares of the business’s stock in a transaction dated Monday, April 1st. The shares were sold at an average price of $72.96, for a total value of $145,920.00. Following the sale, the insider now directly owns 96,304 shares in the company, valued at $7,026,339.84. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. 0.16% of the stock is owned by company insiders.

Institutional Investors Weigh In On Gilead Sciences

Several hedge funds and other institutional investors have recently bought and sold shares of the business. Altshuler Shaham Ltd raised its position in Gilead Sciences by 7.0% in the fourth quarter. Altshuler Shaham Ltd now owns 1,856 shares of the biopharmaceutical company’s stock worth $159,000 after acquiring an additional 121 shares in the last quarter. Nilsine Partners LLC raised its holdings in Gilead Sciences by 1.1% during the 3rd quarter. Nilsine Partners LLC now owns 11,894 shares of the biopharmaceutical company’s stock worth $891,000 after buying an additional 127 shares during the period. Etesian Wealth Advisors Inc. raised its holdings in Gilead Sciences by 0.7% during the 4th quarter. Etesian Wealth Advisors Inc. now owns 18,318 shares of the biopharmaceutical company’s stock worth $1,486,000 after buying an additional 128 shares during the period. Financial Counselors Inc. raised its holdings in Gilead Sciences by 1.5% during the 4th quarter. Financial Counselors Inc. now owns 8,862 shares of the biopharmaceutical company’s stock worth $718,000 after buying an additional 128 shares during the period. Finally, Revolve Wealth Partners LLC raised its holdings in Gilead Sciences by 3.7% during the 4th quarter. Revolve Wealth Partners LLC now owns 3,607 shares of the biopharmaceutical company’s stock worth $292,000 after buying an additional 130 shares during the period. 83.67% of the stock is currently owned by institutional investors.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.